Table 1 Participant characteristics.

From: Towards data-driven biopsychosocial classification of non-specific chronic low back pain: a pilot study

 

Chronic low back pain (n = 21)

Pain-free controls (n = 21)

p

Mean (SD)

Mean (SD)

Ages (years)

35.4 (11.0)

35.6 (11.1)

0.956

Sex (male/female—n)

10/11

10/11

Height (cm)

174.0 (10.3)

172.9 (9.1)

0.718

Weight (kg)

82.4 (16.9)

75.8 (18.9)

0.238

Body mass index (kg/cm2)

27.2 (5.0)

25.3 (6.1)

0.270

Ethnicity n (%)

 Caucasian

17 (81.0)

15 (71.4)

0.304

 Asian

2 (9.5)

6 (28.6)

 None of the above

2 (9.5)

Education n (%)

 Year 12

4 (19.0)

1 (4.7)

0.070

 TAFE certificate

7 (33.3)

3 (14.3)

 Bachelor degree

4 (19.0)

9 (42.9)

 Postgraduate degree

4 (19.0)

8 (38.1)

 None of the above

2 (9.5)

Employment n (%)

 Unemployed

1 (4.8)

0.767

 Casual

3 (14.3)

4 (19.0)

 Part-time

5 (23.8)

5 (23.8)

 Full-time

12 (57.1)

12 (57.1)

Smoking status n (%)

 Current

2 (9.5)

1 (4.7)

0.080

 Prior

4 (19.0)

 Never

15 (71.4)

20 (95.2)

Handedness n (%)

 Left

2 (9.5)

4 (19.0)

0.597

 Right

17 (81.0)

16 (76.2)

 Ambidextrous

2 (9.5)

1 (4.7)

Diagnosed depression/anxiety n (%)

 Depression

3 (14.3)

1 (4.7)

0.422

 Anxiety

4 (19.0)

3 (14.3)

 Both

4 (19.0)

2 (9.5)

 Neither

10 (47.6)

15 (71.4)

Pain duration (months)

76.2 (96.2)

Pain intensity (0–100)

   

 Current

31.9 (19.8)

 Last-week average

38.4 (17.7)

 Last-week worst

57.1 (21.1)

Oswestry Disability Index (0–100)

22.9 (11.1)

Number of pain sites

 Last 7 days

2.8 (1.9)

0.3 (0.7)

 < 0.001

 Last 12 months

5.5 (2.4)

1.4 (1.4)

 < 0.001

 Activity limiting in last 12 months

2.1 (1.8)

0.2 (0.5)

< 0.001

Pain medication usage n (%)*

 Yes

11 (52.4)

 No

10 (47.6)

  1. Data is reported as mean and standard deviation unless otherwise specified.
  2. *Participant 1: Panadol (Paracetamol) and Prozac (Anti-depressant)—last used 4 h prior to testing; Participant 2: Mobic (NSAID)—last used 72 h prior to testing; Participant 3: Voltaren (NSAID) and Panadol (Paracetamol)—last used 4 h prior to testing; Participant 4: Celebrex (NSAID) and Endone (Opioid)—last used 48 h prior to testing; Participant 5: Ibruprofen (NSAID)—last used 240 h prior to testing; Participant 6: Panadol (Paracetamol) and Celebrex (NSAID)—last used 21 days prior to testing; Participant 7: Panadol (Paracetamol)—last used 14 days prior to testing; Participant 8: Voltaren (NSAID) last used 36 h prior to testing; Participant 9: Panadol (Paracetamol)—time last used not reported; Participant 10: Voltaren (NSAID)—last used 96 h prior to testing; Participant 11: Ibruprofen (NSAID)/Paracetamol mixed tablet—last used 5 h prior to testing.
  3. Significant values are in bold.